Status:
COMPLETED
Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
Lead Sponsor:
VA Office of Research and Development
Conditions:
Calcium Pyrophosphate Deposition Disease
Eligibility:
All Genders
21-99 years
Phase:
EARLY_PHASE1
Brief Summary
This study will investigate the hypothesis that probenecid, a medication currently used for gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate deposition disease (CP...
Detailed Description
Objective: The objective of this study is to determine whether pharmacologic doses of the drug probenecid significantly decrease ATP and inorganic pyrophosphate (PPi) levels in the synovial fluid of p...
Eligibility Criteria
Inclusion
- Age \>21 years,
- CPPD diagnosed by Ryan /McCarty criteria
- Joint effusion in a shoulder or knee
Exclusion
- Inability to sign informed consent
- Age \<21 years
- History of renal stones
- Significant renal dysfunction (CKD \>stage 2)
- Blood dyscrasias
- Current use of drugs which interact with probenecid
- Concurrent gout
- Active infection, including bacteremia and overlying cellulitis
- Recent joint trauma
- Intra-articular corticosteroids in the affected joint within three months
Key Trial Info
Start Date :
October 15 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 8 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT02243631
Start Date
October 15 2014
End Date
April 8 2021
Last Update
July 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clement J. Zablocki VA Medical Center, Milwaukee, WI
Milwaukee, Wisconsin, United States, 53295-1000